When was Debiopharm founded?

Debiopharm was founded in 1979 and raised its 1st funding round 40 years after it was founded.

Where is Debiopharm located?

Debiopharm is headquartered in Lausanne, Switzerland.

How many employees does Debiopharm have?

As of Aug 31, 2026, the latest employee count at Debiopharm is 465.

Is Debiopharm a funded company?

Debiopharm is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 14, 2019.

When was the latest funding round of Debiopharm?

Debiopharm's latest funding was a $***** Grant (prize money) round on Oct 19, 2021, with participation from 1 investor.

Where does Debiopharm rank among its competitors?

Debiopharm ranks 43rd amongst 1833 active competitors, of which 94 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Debiopharm?

Debiopharm's top competitors include AbbVie, Gilead and Amgen. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Debiopharm - 2026 Company Profile, Team, Funding & Competitors

Company Details

Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs. It focuses on the development and clinical testing of drug candidates, primarily in oncology and bacterial infections. The company specializes in drug development, manufacturing, and digital health investments.

Website: www.debiopharm.com/
Social
Phone Number: +41 **********

Key Metrics

Founded Year

1979

Location

Lausanne, Switzerland

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Oct 19, 2021, $*****

Investors

CARB-X & 1 more

Ranked

43^rd among 1833 active competitors

Employee Count

465 as on Aug 31, 2026

Investment & Acquisitions

ViewsML & 44 more

Similar Companies

AbbVie & 1861 more

View Debiopharm's full profile

Debiopharm has raised funding over 2 rounds. Its first funding round was on May 14, 2019. Its latest funding round was a Grant (prize money) round on Oct 19, 2021 for $*****. 1 investor participated in its latest round. Debiopharm has 2 institutional investors.

Here is the list of recent funding rounds of Debiopharm:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 19, 2021	5245313	Grant (prize money)	8368252	2176278	9380357	7522923
May 14, 2019	6998285	Grant (prize money)	6135128	9170555	2995065	CARB-X

Access funding benchmarks and valuations. Sign up today!

View details of Debiopharm's funding rounds and investors

The founders of Debiopharm is Rolland-Yves Mauvernay. Bertrand Ducrey is the CEO of Debiopharm.

Here are the details of Debiopharm's key team members:

Rolland-Yves Mauvernay: Former Founder of Debiopharm.
Bertrand Ducrey: CEO of Debiopharm.

Debiopharm's Board of Directors

Debiopharm's board has 8 active members. Jullian-Gaufres Pierre, Zubel Angela, Favre Nicolas and Ducrey Bertrand are part of team and Levy Frederic, Mauvernay Nadine Caille, Currat Vanessa and Mauvernay Thierry are independent board members.

Here is the list of Debiopharm's board of directors:

Name	Type	Representing	Status	Duration
axrxsvz	Team	-	Current	8y 5m
ovrokmd	Team	-	Current	2y 9m
dhqgh{v	Team	-	Current	1y 4m
vquprlp	Team	-	Current	4y 7m
Levy Frederic	Independent board member	-	Current	-
sqakgfg	Independent board member	-	Current	6y 3m
wy{xdfv	Independent board member	-	Current	6y 2m
begikbm	Independent board member	-	Current	5y 9m

View details of Debiopharm's Founder profiles and Board Members

Debiopharm's employee count trend

Debiopharm has 465 employees as of Aug 26. Here is Debiopharm's employee count trend over the years:

Uncover Debiopharm's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Debiopharm include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Debiopharm, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 9 others	83/100
2nd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal ventures & 17 others	81/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
4th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
6th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
7th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	72/100
8th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 11 others	70/100
10th	Genentech 1976, San Francisco (United States), Acquired	R&D company focused on manufacturing drugs for multiple therapeutic areas	$72.5M	Ignite 500, The Column Group & 4 others	68/100
43rd	Debiopharm 1979, Lausanne (Switzerland), Funding Raised	Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs	-	CARB-X, BioVaria	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Debiopharm's competitors? Click here to see the top ones

Debiopharm has made 44 investments in companies including ViewsML and StratifAI. Debiopharm has also acquired 1 companies including Affinium Pharmaceuticals.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 20, 2026	Investments	ViewsML	2022	Vancouver (Canada)
Sep 30, 2025	Investments	StratifAI	2023	Berlin (Germany)
Mar 05, 2025	Investments	MedaSystems	2020	Menlo Park (United States)